PARIS--(BUSINESS WIRE)--Hemispherx Biopharma, Inc. (AMEX: HEB), a biopharmaceutical company engaged in the clinical development of new drug entities for the treatment of pandemic disease threats, announced today a new scientific report on the activity of its experimental therapeutic Ampligen® in combination with approved anti-influenza agents against highly pathogenic avian influenza (HPAI), also known as bird flu.
